Molina Healthcare · MASH or NAFLD with obesity · Versión completa en inglés: /pa-letter/molina-healthcare--mash-nafld/
Carta de PA para Molina Healthcare: MASH or NAFLD with obesity.
Plantilla defensible de carta para Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide). MASH (formerly NASH) and NAFLD with obesity qualify under the obesity-with-comorbidity pathway. Emerging evidence supports GLP-1 for hepatic outcomes.
La carta misma está en inglés porque el revisor del plan la lee en inglés. La envuelve y la firma su clínico.
Cita de política: Molina Clinical Policy, GLP-1 Receptor Agonists.
Nota del plan: Molina Healthcare administers Medicaid managed care in multiple states. Coverage for GLP-1 in obesity follows each state Medicaid PDL, which varies widely (some states cover, most exclude pure obesity indication). T2D pathway is covered nationally with documented A1c and step therapy. Medicare Advantage lines follow CMS rules. CVS Caremark is the PBM for most Molina lines. Verify your specific state Medicaid PDL before submitting an obesity-indication PA.
Nota del plan: Molina Healthcare administers Medicaid managed care in multiple states. Coverage for GLP-1 in obesity follows each state Medicaid PDL, which varies widely (some states cover, most exclude pure obesity indication). T2D pathway is covered nationally with documented A1c and step therapy. Medicare Advantage lines follow CMS rules. CVS Caremark is the PBM for most Molina lines. Verify your specific state Medicaid PDL before submitting an obesity-indication PA.
Lo que CVS Caremark realmente requiere
Molina Healthcare contrata la administración del beneficio de farmacia a CVS Caremark, que adjudica esta PA. Los criterios siguientes provienen de la política clínica del PBM publicada públicamente. Cumpla cada uno antes de enviar.
- BMI greater than or equal to 30, OR BMI greater than or equal to 27 with at least one weight-related comorbidity (T2D, hypertension, dyslipidemia, OSA)
- Documented six-month lifestyle intervention or prior anti-obesity medication trial
- Step therapy through phentermine or orlistat (or documented contraindication / intolerance)
- Treatment plan including continued lifestyle counseling and 5 percent weight-loss target at 6 months
- Reauthorization requires documented adherence and ≥5 percent weight loss from baseline at 12 months
La carta (copiar y editar)
Copie el cuerpo a continuación y péguelo en el portal de su clínico o procesador de textos. Reemplace cada marcador de posición entre [CORCHETES] con datos específicos del paciente antes de enviar. La carta es de su clínico al plan, firmada por su clínico.
[Today's date] Molina Healthcare Prior Authorization Department Submitted via: Molina provider portal, CoverMyMeds or fax 1-866-449-6843 Re: Prior Authorization Request, Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide) Patient: [Patient full name] Member ID: [Plan member ID] Date of birth: [Patient DOB] Group number: [Group number if applicable] Prescriber: [Prescriber full name, NPI, DEA] Prescriber contact: [Phone, fax, email] To the Molina Healthcare Prior Authorization Reviewer, I am the treating clinician for [Patient name]. I am writing to request prior authorization for Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide) for treatment of MASH or NAFLD with obesity (ICD-10: K76.0, K75.81, E66.9). Clinical justification Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) and non-alcoholic fatty liver disease (NAFLD) are common comorbidities in patients with obesity and T2D. Under all major plan PA criteria, MASH or NAFLD documented by imaging, FibroScan or biopsy qualifies as a weight-related comorbidity, opening the obesity pathway at BMI greater than or equal to 27. The ESSENCE trial (semaglutide 2.4 mg in MASH), reported at AASLD 2024 and published in NEJM 2025, demonstrated histologic MASH resolution without worsening fibrosis in 62.9 percent of treated patients versus 34.3 percent on placebo at 72 weeks. The SYNERGY-NASH trial (tirzepatide in MASH) reported similar histologic benefit at 52 weeks. AASLD 2024 practice guidance names GLP-1 RA as appropriate pharmacotherapy in MASH when obesity coexists. Patient-specific findings - [Insert current measurements: weight, height, BMI, blood pressure] - [Insert relevant lab values with dates: A1c, lipid panel, kidney function] - [Insert documentation of comorbidities with ICD-10] - [Insert documentation of prior treatment history, including any prior GLP-1 trials, anti-obesity medication trials or lifestyle intervention] Criteria met per Molina Healthcare policy This request meets the criteria set out in Molina Clinical Policy, GLP-1 Receptor Agonists: - Current weight, height, BMI (BMI greater than or equal to 27 with MASH or NAFLD as the qualifying comorbidity) - MASH or NAFLD documented by FibroScan, ultrasound, MR elastography, MR-PDFF or liver biopsy - ICD-10 K76.0 (NAFLD) or K75.81 (MASH) attached - Most recent ALT, AST, GGT and lipid panel - Hepatology consult letter (strengthens but not always required) Supporting evidence The clinical case for Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide) in this indication is supported by the following registration trials and outcomes data: - ESSENCE (semaglutide 2.4 mg in MASH), Sanyal et al., NEJM 2025 - SYNERGY-NASH (tirzepatide in MASH), Loomba et al., NEJM 2024 - Newsome et al. 2021 (semaglutide in NASH, phase 2), NEJM Plan-specific note Molina Healthcare administers Medicaid managed care in multiple states. Coverage for GLP-1 in obesity follows each state Medicaid PDL, which varies widely (some states cover, most exclude pure obesity indication). T2D pathway is covered nationally with documented A1c and step therapy. Medicare Advantage lines follow CMS rules. CVS Caremark is the PBM for most Molina lines. Verify your specific state Medicaid PDL before submitting an obesity-indication PA. Requested action I am requesting prior authorization for Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide) at the [insert starting dose] starting dose, with planned titration per FDA labeling. I am also requesting that this authorization be granted for a continuous 12-month period subject to documented clinical response, per standard formulary practice. If additional information is required, please contact me directly at [Prescriber phone] or [Prescriber email]. I am available to discuss this case with your medical director if helpful. Thank you for your attention to this request. Sincerely, [Prescriber full signature] [Prescriber printed name, credentials] [Prescriber NPI] [Practice name and address] Attachments: - Current vital signs and BMI calculation - Most recent relevant labs - Documentation of comorbidities - Documentation of prior treatment trials - Sleep study report (if OSA indication) - Cardiac history documentation (if CV indication)
Aviso legal
Plantillas educativas únicamente. No constituyen asesoramiento legal ni médico. Las cartas deben ser firmadas por el clínico tratante (MD, DO, NP, PA) con autoridad de prescripción. Cada plan cambia los criterios trimestralmente. Verifique con el boletín de política de PA más reciente de su plan antes de enviar. No invente hallazgos clínicos. No altere la firma de un clínico.
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. No removal of unfavorable information at advertiser request. Pricing is pulled from each program's public-facing page weekly.